Abstract
Abstract Previous studies demonstrated that gene expression profiles from formalin-fixed paraffin-embedded (FFPE) tissues are largely comparable to fresh frozen matched tissue. This technology can assist in discovering biomarkers of lung cancer prognosis and progression by vastly increasing in the potential resources available for cancer research. In this study, we investigated the potential use of the Whole-Genome DASL HT Assay (Illumina, San Diego, CA) for global expression profiling in FFPE tissues obtained by surgical biopsy from patients with early stage non-small cell lung cancer (NSCLC). We obtained high-quality microarray data on 26 pairs of tumor/non-affected tissues, including 18 pairs of adenocarcinoma and 8 pairs of squamous carcinomas. Among genes differentially expressed between squamous carcinomas and adjacent non-affected lung tissue, we found that the AKR1C1 gene, encoding an aldo-keto reductases, was increased strongly in tumors (fold change: 3.0; p=0.02). This finding was consistent with previous reports that overexpression of AKR1C1 gene as an indicator of poor prognosis and chemoresistance in NSCLC. During pathway-based analysis using GeneGo database, we found that differentially expressed genes of adenocarcinoma were significantly enriched in the pathway of cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling; and differentially expressed genes of squamous carcinomas were significantly enriched in the pathway of Lung Neoplasms_Signal transduction. Our study demonstrates that with DASL expression profiling technology, genome-wide expression profiles can be successfully generated from FFPE lung tissues. Support: CA092824 and CA CA90578, and CA074386 from NCI Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-399. doi:1538-7445.AM2012-LB-399
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
